Get the Stockscreener App
7.13
4.85%
0.33
Pre-market:
7.13
Biodexa Pharmaceuticals Plc Adr stock is traded at $7.13, with a volume of 23,594.
It is up +4.85% in the last 24 hours and down -18.14% over the past month.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
See More
Previous Close:
$6.80
Open:
$7
24h Volume:
23,594
Relative Volume:
0.10
Market Cap:
$34.14M
Revenue:
$644.60K
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.00851
EPS:
-837.9618
Net Cash Flow:
$-9.02M
1W Performance:
+6.42%
1M Performance:
-18.14%
6M Performance:
-82.48%
1Y Performance:
-95.00%
1-Day Range:
$6.6796
$7.25
1-Week Range:
$6.6228
$7.3217
52-Week Range:
$5.852
$163.10
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc Adr
Sector
Industry
Phone
-
Address
-
Compare BDRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
7.13 | 34.14M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-24 | Initiated | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com Nigeria
Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewswire
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Results of Annual General Meeting - GlobeNewswire
Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan
Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan
Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com
Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan
Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals changes share nominal value - Investing.com
Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India
Biodexa shareholders approve all resolutions at general meeting - Investing.com
Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority - Stock Titan
Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan
Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa secures additional $3M for cancer drug trial - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com
Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India
Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire
Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan
Preliminary Results for the Year Ended 31 December 2024 - GlobeNewswire
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):